{"transactions":[{"id":4618399,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T21:05:32.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":7839,"price":156.22,"value":1224608.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":517797,"source":{"system":"sec-edgar","filing":"0001201096-26-000018","document":"wk-form4_1789506329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000120109626000018/wk-form4_1789506329.xml","form_type":"4"}},{"id":4618398,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T21:05:32.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":14343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":525636,"source":{"system":"sec-edgar","filing":"0001201096-26-000018","document":"wk-form4_1789506329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000120109626000018/wk-form4_1789506329.xml","form_type":"4"}},{"id":712526,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-08T22:54:59.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":20604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027."}],"balance_after":20604,"derivative":{"exercise_price":12.2,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":20604},"source":{"system":"sec-edgar","filing":"0001201096-26-000016","document":"wk-form4_1783551296.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000120109626000016/wk-form4_1783551296.xml","form_type":"4"}},{"id":712525,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T22:54:59.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":10302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that shall fully vest on the first anniversary of the date of grant."}],"balance_after":21680,"source":{"system":"sec-edgar","filing":"0001201096-26-000016","document":"wk-form4_1783551296.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000120109626000016/wk-form4_1783551296.xml","form_type":"4"}},{"id":733724,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:02:03.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":7527,"price":12.31,"value":92657.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 27, 2025."}],"balance_after":11378,"source":{"system":"sec-edgar","filing":"0001201096-26-000014","document":"wk-form4_1781726521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000120109626000014/wk-form4_1781726521.xml","form_type":"4"}},{"id":759327,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2026-05-29T22:05:50.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":5248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 monthly installments beginning June 27, 2026."}],"balance_after":5248,"derivative":{"exercise_price":155.83,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":5248},"source":{"system":"sec-edgar","filing":"0001201096-26-000012","document":"wk-form4_1780092347.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000012/wk-form4_1780092347.xml","form_type":"4"}},{"id":768843,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2026-05-21T21:49:51.000Z","date":"2026-05-19","kind":"exercise","planned":true,"acquired":false,"shares":205088,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017.  These options were due to expire on February 6, 2027."}],"balance_after":0,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":205088},"source":{"system":"sec-edgar","filing":"0001201096-26-000010","document":"wk-form4_1779400189.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000010/wk-form4_1779400189.xml","form_type":"4"}},{"id":768842,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T21:49:51.000Z","date":"2026-05-19","kind":"sale","planned":true,"acquired":false,"shares":245088,"price":154.3318,"value":37824872.1984,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $153.30 to $156.59. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"511,293 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":511293,"source":{"system":"sec-edgar","filing":"0001201096-26-000010","document":"wk-form4_1779400189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000010/wk-form4_1779400189.xml","form_type":"4"}},{"id":768841,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T21:49:51.000Z","date":"2026-05-19","kind":"exercise","planned":true,"acquired":true,"shares":205088,"price":43.24,"value":8868005.12,"ownership":{"direct":true},"balance_after":756381,"source":{"system":"sec-edgar","filing":"0001201096-26-000010","document":"wk-form4_1779400189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000010/wk-form4_1779400189.xml","form_type":"4"}},{"id":902238,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:44:32.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":5377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, vested as to 5,377 shares on February 13, 2026, and will vest as to 5,377 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, vested as to 5,377 shares on February 13, 2026, and will vest as to 5,377 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":5377,"derivative":{"underlying":"Common Stock","underlying_shares":5377},"source":{"system":"sec-edgar","filing":"0001201096-26-000005","document":"wk-form4_1771368269.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000005/wk-form4_1771368269.xml","form_type":"4"}},{"id":902237,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:44:32.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":5604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, vested as to 5,604 shares on February 13, 2026, and will vest as to 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, vested as to 5,604 shares on February 13, 2026, and will vest as to 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":11208,"derivative":{"underlying":"Common Stock","underlying_shares":5604},"source":{"system":"sec-edgar","filing":"0001201096-26-000005","document":"wk-form4_1771368269.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000005/wk-form4_1771368269.xml","form_type":"4"}},{"id":902236,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-17T22:44:32.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":34380,"price":124.12,"value":4267245.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"551,293 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":551293,"source":{"system":"sec-edgar","filing":"0001201096-26-000005","document":"wk-form4_1771368269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000005/wk-form4_1771368269.xml","form_type":"4"}},{"id":902235,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-17T22:44:32.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":63724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award."}],"balance_after":585673,"source":{"system":"sec-edgar","filing":"0001201096-26-000005","document":"wk-form4_1771368269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000005/wk-form4_1771368269.xml","form_type":"4"}},{"id":902234,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-17T22:44:32.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":2901,"price":124.12,"value":360072.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":521949,"source":{"system":"sec-edgar","filing":"0001201096-26-000005","document":"wk-form4_1771368269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000005/wk-form4_1771368269.xml","form_type":"4"}},{"id":902233,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-17T22:44:32.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":5377,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":524850,"source":{"system":"sec-edgar","filing":"0001201096-26-000005","document":"wk-form4_1771368269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000005/wk-form4_1771368269.xml","form_type":"4"}},{"id":902232,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-17T22:44:32.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":3024,"price":124.12,"value":375338.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":519473,"source":{"system":"sec-edgar","filing":"0001201096-26-000005","document":"wk-form4_1771368269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000005/wk-form4_1771368269.xml","form_type":"4"}},{"id":902231,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-17T22:44:32.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":5604,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":522497,"source":{"system":"sec-edgar","filing":"0001201096-26-000005","document":"wk-form4_1771368269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000005/wk-form4_1771368269.xml","form_type":"4"}},{"id":922914,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-02-03T23:02:33.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":5142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and vested as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and vested as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5142},"source":{"system":"sec-edgar","filing":"0001201096-26-000003","document":"wk-form4_1770159750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000003/wk-form4_1770159750.xml","form_type":"4"}},{"id":922913,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-03T23:02:33.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":2845,"price":136.06,"value":387090.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\"). No shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"516,893 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":516893,"source":{"system":"sec-edgar","filing":"0001201096-26-000003","document":"wk-form4_1770159750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000003/wk-form4_1770159750.xml","form_type":"4"}},{"id":922912,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-03T23:02:33.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":true,"shares":5142,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":519738,"source":{"system":"sec-edgar","filing":"0001201096-26-000003","document":"wk-form4_1770159750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000003/wk-form4_1770159750.xml","form_type":"4"}},{"id":1070826,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2025-08-11T20:55:16.000Z","date":"2025-08-07","kind":"exercise","planned":true,"acquired":false,"shares":106322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5,  2016. These options were due to expire on February 5, 2026."}],"balance_after":0,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":106322},"source":{"system":"sec-edgar","filing":"0000914475-25-000166","document":"wk-form4_1754945711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000166/wk-form4_1754945711.xml","form_type":"4"}},{"id":1070825,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-11T20:55:16.000Z","date":"2025-08-07","kind":"sale","planned":true,"acquired":false,"shares":106322,"price":126.4111,"value":13440280.9742,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2025. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $124.80 to $129.03. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":514596,"source":{"system":"sec-edgar","filing":"0000914475-25-000166","document":"wk-form4_1754945711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000166/wk-form4_1754945711.xml","form_type":"4"}},{"id":1070824,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-11T20:55:16.000Z","date":"2025-08-07","kind":"exercise","planned":true,"acquired":true,"shares":106322,"price":35.99,"value":3826528.78,"ownership":{"direct":true},"balance_after":620918,"source":{"system":"sec-edgar","filing":"0000914475-25-000166","document":"wk-form4_1754945711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000166/wk-form4_1754945711.xml","form_type":"4"}},{"id":1109614,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T23:30:12.000Z","date":"2025-06-12","kind":"grant","planned":true,"acquired":true,"shares":27372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 12, 2025, such that the total number of shares will be fully vested on June 12, 2026."}],"balance_after":27372,"derivative":{"exercise_price":9.43,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":27372},"source":{"system":"sec-edgar","filing":"0001127602-25-017597","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000112760225017597/form4.xml","form_type":"4"}},{"id":1109613,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T23:30:12.000Z","date":"2025-06-16","kind":"sale","planned":true,"acquired":false,"shares":3173,"price":9.22,"value":29255.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024."}],"balance_after":18905,"source":{"system":"sec-edgar","filing":"0001127602-25-017597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000112760225017597/form4.xml","form_type":"4"}},{"id":1109612,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T23:30:12.000Z","date":"2025-06-12","kind":"grant","planned":true,"acquired":true,"shares":13686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that shall fully vest on the first anniversary of the date of grant."}],"balance_after":22078,"source":{"system":"sec-edgar","filing":"0001127602-25-017597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000112760225017597/form4.xml","form_type":"4"}},{"id":1131042,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T22:15:13.000Z","date":"2025-05-27","kind":"sale","planned":true,"acquired":false,"shares":9613,"price":120.3798,"value":1157211.0174,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.62 to $120.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":514596,"source":{"system":"sec-edgar","filing":"0000914475-25-000137","document":"wk-form4_1748556907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000137/wk-form4_1748556907.xml","form_type":"4"}},{"id":1138148,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2025-05-22T21:29:54.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":6610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 monthly installments beginning June 21, 2025."}],"balance_after":6610,"derivative":{"exercise_price":120.56,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":6610},"source":{"system":"sec-edgar","filing":"0000914475-25-000132","document":"wk-form4_1747949388.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000132/wk-form4_1747949388.xml","form_type":"4"}},{"id":1268345,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:57:31.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":5603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, and will vest as to 5,604 shares on February 13, 2026, 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, and will vest as to 5,604 shares on February 13, 2026, 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":16812,"derivative":{"underlying":"Common Stock","underlying_shares":5603},"source":{"system":"sec-edgar","filing":"0000914475-25-000073","document":"wk-form4_1739577443.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000073/wk-form4_1739577443.xml","form_type":"4"}},{"id":1268344,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:57:31.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":5376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, and will vest as to 5,377 shares on February 13, 2026, and 5,377 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, and will vest as to 5,377 shares on February 13, 2026, and 5,377 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":10754,"derivative":{"underlying":"Common Stock","underlying_shares":5376},"source":{"system":"sec-edgar","filing":"0000914475-25-000073","document":"wk-form4_1739577443.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000073/wk-form4_1739577443.xml","form_type":"4"}},{"id":1268343,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-14T23:57:31.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":3012,"price":116.6832,"value":351449.7984,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $117.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":524209,"source":{"system":"sec-edgar","filing":"0000914475-25-000073","document":"wk-form4_1739577443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000073/wk-form4_1739577443.xml","form_type":"4"}},{"id":1268342,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-14T23:57:31.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":5603,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":527221,"source":{"system":"sec-edgar","filing":"0000914475-25-000073","document":"wk-form4_1739577443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000073/wk-form4_1739577443.xml","form_type":"4"}},{"id":1268341,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-14T23:57:31.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":2832,"price":116.6895,"value":330464.664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.92 to $117.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":521618,"source":{"system":"sec-edgar","filing":"0000914475-25-000073","document":"wk-form4_1739577443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000073/wk-form4_1739577443.xml","form_type":"4"}},{"id":1268340,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-14T23:57:31.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":5376,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":524450,"source":{"system":"sec-edgar","filing":"0000914475-25-000073","document":"wk-form4_1739577443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000073/wk-form4_1739577443.xml","form_type":"4"}},{"id":1272437,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-02-12T23:56:08.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":false,"shares":4318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 4,317 shares on February 8, 2022, vested as to 4,317 shares on February 8, 2023, vested as to 4,317 shares on February 8, 2024, and vested as to 4,318 shares on February 8, 2025, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 4,317 shares on February 8, 2022, vested as to 4,317 shares on February 8, 2023, vested as to 4,317 shares on February 8, 2024, and vested as to 4,318 shares on February 8, 2025, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4318},"source":{"system":"sec-edgar","filing":"0000914475-25-000052","document":"wk-form4_1739404561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000052/wk-form4_1739404561.xml","form_type":"4"}},{"id":1272436,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-12T23:56:08.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":2274,"price":118.3673,"value":269167.2402,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.06 to $123.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":519074,"source":{"system":"sec-edgar","filing":"0000914475-25-000052","document":"wk-form4_1739404561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000052/wk-form4_1739404561.xml","form_type":"4"}},{"id":1272435,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-12T23:56:08.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":true,"shares":4318,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":521348,"source":{"system":"sec-edgar","filing":"0000914475-25-000052","document":"wk-form4_1739404561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000052/wk-form4_1739404561.xml","form_type":"4"}},{"id":1285998,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-02-04T22:58:32.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":false,"shares":5141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and will vest as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and will vest as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":5142,"derivative":{"underlying":"Common Stock","underlying_shares":5141},"source":{"system":"sec-edgar","filing":"0000914475-25-000031","document":"wk-form4_1738709906.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000031/wk-form4_1738709906.xml","form_type":"4"}},{"id":1285997,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T22:58:32.000Z","date":"2025-01-31","kind":"sale","planned":true,"acquired":false,"shares":2707,"price":152.9246,"value":413966.8922,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.85 to $154.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":517030,"source":{"system":"sec-edgar","filing":"0000914475-25-000031","document":"wk-form4_1738709906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000031/wk-form4_1738709906.xml","form_type":"4"}},{"id":1285996,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T22:58:32.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":true,"shares":5141,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":519737,"source":{"system":"sec-edgar","filing":"0000914475-25-000031","document":"wk-form4_1738709906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000031/wk-form4_1738709906.xml","form_type":"4"}},{"id":1292219,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2025-01-30T00:03:43.000Z","date":"2025-01-27","kind":"exercise","planned":true,"acquired":false,"shares":146105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 3, 2015 and vested in 48 equal monthly installments beginning on March 3, 2015. These options were due to expire on February 3, 2025."}],"balance_after":0,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":146105},"source":{"system":"sec-edgar","filing":"0000914475-25-000009","document":"wk-form4_1738195415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000009/wk-form4_1738195415.xml","form_type":"4"}},{"id":1292218,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-30T00:03:43.000Z","date":"2025-01-27","kind":"sale","planned":true,"acquired":false,"shares":146105,"price":149.4576,"value":21836502.648,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy\nrestricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $147.20 to $151.49. The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":514596,"source":{"system":"sec-edgar","filing":"0000914475-25-000009","document":"wk-form4_1738195415.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000009/wk-form4_1738195415.xml","form_type":"4"}},{"id":1292217,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-30T00:03:43.000Z","date":"2025-01-27","kind":"exercise","planned":true,"acquired":true,"shares":146105,"price":32.99,"value":4820003.95,"ownership":{"direct":true},"balance_after":660701,"source":{"system":"sec-edgar","filing":"0000914475-25-000009","document":"wk-form4_1738195415.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000009/wk-form4_1738195415.xml","form_type":"4"}},{"id":1396612,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-01T20:09:37.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":2654,"price":20.68,"value":54884.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale was pursuant to a 10b5-1 plan arranged to cover withholding taxes upon vesting of restricted stock units."}],"balance_after":8392,"source":{"system":"sec-edgar","filing":"0001127602-24-024672","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000112760224024672/form4.xml","form_type":"4"}},{"id":1477036,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T20:22:00.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":11971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 13, 2024, such that the total number of shares will be fully vested on June 13, 2025."}],"balance_after":11971,"derivative":{"exercise_price":21.31,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":11971},"source":{"system":"sec-edgar","filing":"0001127602-24-018831","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000112760224018831/form4.xml","form_type":"4"}},{"id":1477035,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-17T20:22:00.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":5986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that shall fully vest on the first anniversary of the date of grant."}],"balance_after":11046,"source":{"system":"sec-edgar","filing":"0001127602-24-018831","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000112760224018831/form4.xml","form_type":"4"}},{"id":1641729,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-02-15T22:43:40.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":22415,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."}],"balance_after":22415,"derivative":{"underlying":"Common Stock","underlying_shares":22415},"source":{"system":"sec-edgar","filing":"0000914475-24-000073","document":"wk-form4_1708037005.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000073/wk-form4_1708037005.xml","form_type":"4"}},{"id":1641728,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2024-02-15T22:43:40.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":112644,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":112644,"derivative":{"exercise_price":133.84,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":112644},"source":{"system":"sec-edgar","filing":"0000914475-24-000073","document":"wk-form4_1708037005.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000073/wk-form4_1708037005.xml","form_type":"4"}},{"id":1641727,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:43:40.000Z","date":"2024-02-13","kind":"sale","planned":true,"acquired":false,"shares":2832,"price":133.0157,"value":376700.4624,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,832 shares of common stock issued upon vesting of 5,376 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,544) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.98 to $134.56.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":514596,"source":{"system":"sec-edgar","filing":"0000914475-24-000073","document":"wk-form4_1708037005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000073/wk-form4_1708037005.xml","form_type":"4"}},{"id":1640745,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-02-15T21:02:46.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":53,"price":19.12,"value":1013.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased by the reporting person's investment advisor in a managed account, without the knowledge of the reporting person."}],"balance_after":5060,"source":{"system":"sec-edgar","filing":"0001127602-24-005195","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000112760224005195/form4.xml","form_type":"4"}},{"id":1644099,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Incentive Stock Option","published_at":"2024-02-14T22:17:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2312,"price":43.24,"value":99970.88,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017."}],"balance_after":0,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":2312},"source":{"system":"sec-edgar","filing":"0000914475-24-000056","document":"wk-form4_1707948998.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000056/wk-form4_1707948998.xml","form_type":"4"}},{"id":1644098,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Incentive Stock Option","published_at":"2024-02-14T22:17:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2778,"price":35.99,"value":99980.22,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016."}],"balance_after":0,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":2778},"source":{"system":"sec-edgar","filing":"0000914475-24-000056","document":"wk-form4_1707948998.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000056/wk-form4_1707948998.xml","form_type":"4"}},{"id":1644097,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-14T22:17:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":2312,"price":43.24,"value":99970.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":512052,"source":{"system":"sec-edgar","filing":"0000914475-24-000056","document":"wk-form4_1707948998.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000056/wk-form4_1707948998.xml","form_type":"4"}},{"id":1644096,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-14T22:17:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":2778,"price":35.99,"value":99980.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."}],"balance_after":509740,"source":{"system":"sec-edgar","filing":"0000914475-24-000056","document":"wk-form4_1707948998.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000056/wk-form4_1707948998.xml","form_type":"4"}},{"id":1654156,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:21:44.000Z","date":"2024-02-08","kind":"sale","planned":true,"acquired":false,"shares":2274,"price":134.1479,"value":305052.3246,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February  8, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.75 to $136.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":506962,"source":{"system":"sec-edgar","filing":"0000914475-24-000046","document":"wk-form4_1707438093.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000046/wk-form4_1707438093.xml","form_type":"4"}},{"id":1654155,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:21:44.000Z","date":"2024-02-06","kind":"sale","planned":true,"acquired":false,"shares":3040,"price":142.1771,"value":432218.384,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 3,040 shares of common stock issued upon vesting of 5,771 restricted stock units on February  6, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,731) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":504919,"source":{"system":"sec-edgar","filing":"0000914475-24-000046","document":"wk-form4_1707438093.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000046/wk-form4_1707438093.xml","form_type":"4"}},{"id":1662749,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-03T00:21:56.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":2707,"price":140.6888,"value":380844.5816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,707 shares of common stock issued upon vesting of 5,141 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,434) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.74 to $142.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":502188,"source":{"system":"sec-edgar","filing":"0000914475-24-000028","document":"wk-form4_1706919702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000028/wk-form4_1706919702.xml","form_type":"4"}},{"id":1681950,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-01-10T21:31:24.000Z","date":"2024-01-09","kind":"exercise","planned":true,"acquired":false,"shares":62023,"price":19.59,"value":1215030.57,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024."}],"balance_after":0,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":62023},"source":{"system":"sec-edgar","filing":"0000914475-24-000009","document":"wk-form4_1704922274.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000009/wk-form4_1704922274.xml","form_type":"4"}},{"id":1681949,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-01-10T21:31:24.000Z","date":"2024-01-08","kind":"exercise","planned":true,"acquired":false,"shares":105835,"price":19.59,"value":2073307.65,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024."}],"balance_after":62023,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":105835},"source":{"system":"sec-edgar","filing":"0000914475-24-000009","document":"wk-form4_1704922274.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000009/wk-form4_1704922274.xml","form_type":"4"}},{"id":1681948,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-10T21:31:24.000Z","date":"2024-01-09","kind":"sale","planned":true,"acquired":false,"shares":62023,"price":134.0131,"value":8311894.5013,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 22, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.28 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":499754,"source":{"system":"sec-edgar","filing":"0000914475-24-000009","document":"wk-form4_1704922274.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000009/wk-form4_1704922274.xml","form_type":"4"}},{"id":1681947,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-10T21:31:24.000Z","date":"2024-01-09","kind":"exercise","planned":true,"acquired":true,"shares":62023,"price":19.59,"value":1215030.57,"ownership":{"direct":true},"balance_after":561777,"source":{"system":"sec-edgar","filing":"0000914475-24-000009","document":"wk-form4_1704922274.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000009/wk-form4_1704922274.xml","form_type":"4"}},{"id":1681946,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-10T21:31:24.000Z","date":"2024-01-08","kind":"sale","planned":true,"acquired":false,"shares":105835,"price":132.4375,"value":14016522.8125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 22, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.72 to $133.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":499754,"source":{"system":"sec-edgar","filing":"0000914475-24-000009","document":"wk-form4_1704922274.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000009/wk-form4_1704922274.xml","form_type":"4"}},{"id":1681945,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-10T21:31:24.000Z","date":"2024-01-08","kind":"exercise","planned":true,"acquired":true,"shares":105835,"price":19.59,"value":2073307.65,"ownership":{"direct":true},"balance_after":605589,"source":{"system":"sec-edgar","filing":"0000914475-24-000009","document":"wk-form4_1704922274.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000009/wk-form4_1704922274.xml","form_type":"4"}},{"id":1799014,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-24T00:08:50.000Z","date":"2023-08-21","kind":"sale","planned":true,"acquired":false,"shares":9328,"price":107.3988,"value":1001816.0064,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 9,328 shares of common stock issued upon vesting of 17,717 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (8,389) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":499754,"source":{"system":"sec-edgar","filing":"0001209191-23-047137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123047137/doc4.xml","form_type":"4"}},{"id":1846307,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-22T21:55:07.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":10013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 20, 2023, such that the total number of shares will be fully vested on June 20, 2024."}],"balance_after":10013,"derivative":{"exercise_price":26.19,"expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":10013},"source":{"system":"sec-edgar","filing":"0001127602-23-019287","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000112760223019287/form4.xml","form_type":"4"}},{"id":1846306,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-22T21:55:07.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":5007,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that shall fully vest on the first anniversary of the date of grant."}],"balance_after":5007,"source":{"system":"sec-edgar","filing":"0001127602-23-019287","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000112760223019287/form4.xml","form_type":"4"}},{"id":2014201,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-02-16T00:11:55.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":21506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."}],"balance_after":21506,"derivative":{"underlying":"Common Stock","underlying_shares":21506},"source":{"system":"sec-edgar","filing":"0001209191-23-009886","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009886/doc4.xml","form_type":"4"}},{"id":2014200,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-02-16T00:11:55.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":133656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":133656,"derivative":{"exercise_price":103.52,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":133656},"source":{"system":"sec-edgar","filing":"0001209191-23-009886","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009886/doc4.xml","form_type":"4"}},{"id":2026998,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:28:14.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":2274,"price":104.3028,"value":237184.5672,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.72 to $105.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":491365,"source":{"system":"sec-edgar","filing":"0001209191-23-007912","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007912/doc4.xml","form_type":"4"}},{"id":2026997,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:28:14.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":20482,"price":102.4338,"value":2098049.0916,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 20,482 shares of common stock issued upon vesting of 38,874 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (18,392) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F6","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.03 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":489322,"source":{"system":"sec-edgar","filing":"0001209191-23-007912","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007912/doc4.xml","form_type":"4"}},{"id":2026996,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:28:14.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":3248,"price":102.2985,"value":332265.528,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 3,248 shares of common stock issued upon vesting of 6,170 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,922) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.39 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":470930,"source":{"system":"sec-edgar","filing":"0001209191-23-007912","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007912/doc4.xml","form_type":"4"}},{"id":2026995,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:28:14.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":3040,"price":105.6772,"value":321258.688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 3,040 shares of common stock issued upon vesting of 5,770 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,730) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.64 to $108.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":468008,"source":{"system":"sec-edgar","filing":"0001209191-23-007912","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007912/doc4.xml","form_type":"4"}},{"id":2037154,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-02T22:19:02.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":2707,"price":110.0839,"value":297997.1173,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,707 shares of common stock issued upon vesting of 5,141 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,434) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $111.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":465278,"source":{"system":"sec-edgar","filing":"0001209191-23-006276","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123006276/doc4.xml","form_type":"4"}},{"id":2220988,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-27T20:50:44.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":21412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023."}],"balance_after":21412,"derivative":{"exercise_price":26.58,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":21412},"source":{"system":"sec-edgar","filing":"0001127602-22-018171","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000112760222018171/form4.xml","form_type":"4"}},{"id":2406975,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:00:56.000Z","date":"2022-02-08","kind":"sale","acquired":false,"shares":2274,"price":79.4932,"value":180767.5368,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $78.98 to $79.97. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":462844,"source":{"system":"sec-edgar","filing":"0001209191-22-008211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008211/doc4.xml","form_type":"4"}},{"id":2406974,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:00:56.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":3040,"price":80.7994,"value":245630.176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 3,040 shares of common stock issued upon vesting of 5,770 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,730) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.73 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":460801,"source":{"system":"sec-edgar","filing":"0001209191-22-008211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008211/doc4.xml","form_type":"4"}},{"id":2406973,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:00:56.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":3248,"price":80.8245,"value":262517.976,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.69 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":458071,"source":{"system":"sec-edgar","filing":"0001209191-22-008211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008211/doc4.xml","form_type":"4"}},{"id":2406972,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:00:56.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":2422,"price":80.8252,"value":195758.6344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,422 shares of common stock issued upon vesting of 4,600 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,178) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.77 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":455150,"source":{"system":"sec-edgar","filing":"0001209191-22-008211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008211/doc4.xml","form_type":"4"}},{"id":2417555,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-02-03T00:51:15.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":20565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."}],"balance_after":20565,"derivative":{"underlying":"Common Stock","underlying_shares":20565},"source":{"system":"sec-edgar","filing":"0001209191-22-006580","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006580/doc4.xml","form_type":"4"}},{"id":2417554,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2022-02-03T00:51:15.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":140049,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":140049,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":140049},"source":{"system":"sec-edgar","filing":"0001209191-22-006580","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006580/doc4.xml","form_type":"4"}},{"id":2654583,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-26T00:01:08.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":9728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 24, 2021, such that the total number of shares will be fully vested on June 24, 2022."}],"balance_after":9728,"derivative":{"exercise_price":36.01,"expiration_date":"2031-06-24","underlying":"Common Stock","underlying_shares":9728},"source":{"system":"sec-edgar","filing":"0001415889-21-003232","document":"form4-06252021_080622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000141588921003232/form4-06252021_080622.xml","form_type":"4"}},{"id":2769847,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-03-29T10:19:40.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":113863,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":113863,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":113863},"source":{"system":"sec-edgar","filing":"0001209191-21-023379","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121023379/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-09"}},{"id":2872926,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-02-10T02:17:21.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":17269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."}],"balance_after":17269,"derivative":{"underlying":"Common Stock","underlying_shares":17269},"source":{"system":"sec-edgar","filing":"0001209191-21-009117","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009117/doc4.xml","form_type":"4"}},{"id":2872925,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-02-10T02:17:21.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":103609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":103609,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":103609},"source":{"system":"sec-edgar","filing":"0001209191-21-009117","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009117/doc4.xml","form_type":"4"}},{"id":2872924,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:17:21.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":3248,"price":116.7147,"value":379089.3456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.91 to $117.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":452972,"source":{"system":"sec-edgar","filing":"0001209191-21-009117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009117/doc4.xml","form_type":"4"}},{"id":2872923,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:17:21.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":4343,"price":116.7394,"value":506999.2142,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 4,343 shares of common stock issued upon vesting of 8,250 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (3,907) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.89 to $117.86. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":450051,"source":{"system":"sec-edgar","filing":"0001209191-21-009117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009117/doc4.xml","form_type":"4"}},{"id":2872922,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:17:21.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":2875,"price":116.7913,"value":335774.9875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 2,875 shares of common stock issued upon vesting of 5,770 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,895) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.91 to $117.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":446144,"source":{"system":"sec-edgar","filing":"0001209191-21-009117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009117/doc4.xml","form_type":"4"}},{"id":2872921,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:17:21.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":2422,"price":114.1637,"value":276504.4814,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,422 shares of common stock issued upon vesting of 4,600 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,178) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.51 to $116.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":443249,"source":{"system":"sec-edgar","filing":"0001209191-21-009117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009117/doc4.xml","form_type":"4"}},{"id":2909936,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2021-01-12T21:16:10.000Z","date":"2021-01-08","kind":"exercise","acquired":false,"shares":164801,"price":8.65,"value":1425528.65,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option granted January 10, 2013 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":8.65,"expiration_date":"2023-01-10","underlying":"Common Stock","underlying_shares":164801},"source":{"system":"sec-edgar","filing":"0001209191-21-003235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121003235/doc4.xml","form_type":"4"}},{"id":2909935,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2021-01-12T21:16:10.000Z","date":"2021-01-08","kind":"exercise","acquired":false,"shares":143449,"price":8.66,"value":1242268.34,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted January 12, 2012 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":8.66,"expiration_date":"2022-01-12","underlying":"Common Stock","underlying_shares":143449},"source":{"system":"sec-edgar","filing":"0001209191-21-003235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121003235/doc4.xml","form_type":"4"}},{"id":2909934,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-12T21:16:10.000Z","date":"2021-01-08","kind":"sale","acquired":false,"shares":164801,"price":110.2225,"value":18164778.2225,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $111.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":441071,"source":{"system":"sec-edgar","filing":"0001209191-21-003235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121003235/doc4.xml","form_type":"4"}},{"id":2909933,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-12T21:16:10.000Z","date":"2021-01-08","kind":"exercise","acquired":true,"shares":164801,"price":8.65,"value":1425528.65,"ownership":{"direct":true},"balance_after":605872,"source":{"system":"sec-edgar","filing":"0001209191-21-003235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121003235/doc4.xml","form_type":"4"}},{"id":2909932,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-12T21:16:10.000Z","date":"2021-01-08","kind":"sale","acquired":false,"shares":143449,"price":110.2071,"value":15809098.2879,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $111.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":441071,"source":{"system":"sec-edgar","filing":"0001209191-21-003235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121003235/doc4.xml","form_type":"4"}},{"id":2909931,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-12T21:16:10.000Z","date":"2021-01-08","kind":"exercise","acquired":true,"shares":143449,"price":8.66,"value":1242268.34,"ownership":{"direct":true},"balance_after":584520,"source":{"system":"sec-edgar","filing":"0001209191-21-003235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121003235/doc4.xml","form_type":"4"}},{"id":2980247,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-11-16T23:16:04.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":3390,"price":90.781,"value":307747.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 3,390 shares of common stock issued upon vesting of 6,440 performance restricted stock units to cover withholding taxes, with the balance of the shares (3,050) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $89.05 to $92.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":441071,"source":{"system":"sec-edgar","filing":"0001209191-20-058545","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120058545/doc4.xml","form_type":"4"}},{"id":3065174,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-08-07T23:29:27.000Z","date":"2020-08-05","kind":"sale","acquired":false,"shares":3390,"price":118.9089,"value":403101.171,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 3,390 shares of common stock issued upon vesting of 6,440 performance restricted stock units to cover withholding\ntaxes, with the balance of the shares (3,050) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a\nbroker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction\ndate in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan\nsubsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.16 to $120.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":438021,"source":{"system":"sec-edgar","filing":"0001209191-20-045753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120045753/doc4.xml","form_type":"4"}},{"id":3097454,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T00:24:36.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":13953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 25, 2020, such that the total number of shares will be fully vested on June 25, 2021."}],"balance_after":13953,"derivative":{"exercise_price":33.42,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":13953},"source":{"system":"sec-edgar","filing":"0001209191-20-039288","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000120919120039288/doc4.xml","form_type":"4"}},{"id":3168577,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-04-29T00:41:44.000Z","date":"2020-04-24","kind":"sale","acquired":false,"shares":2906,"price":99.4548,"value":289015.6488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,906 shares of common stock issued upon vesting of 5,520 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (2,614) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":434971,"source":{"system":"sec-edgar","filing":"0001209191-20-026068","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120026068/doc4.xml","form_type":"4"}},{"id":3280433,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-02-12T00:14:28.000Z","date":"2020-02-07","kind":"sale","acquired":false,"shares":3248,"price":103.3547,"value":335696.0656,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.985 to $104.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":432357,"source":{"system":"sec-edgar","filing":"0001209191-20-008494","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008494/doc4.xml","form_type":"4"}},{"id":3285279,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2020-02-07T23:44:56.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":23081,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024."}],"balance_after":23081,"derivative":{"underlying":"Common Stock","underlying_shares":23081},"source":{"system":"sec-edgar","filing":"0001209191-20-007681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007681/doc4.xml","form_type":"4"}}],"next_cursor":"2020-02-07T23:44:56.000000Z,3285279"}